SCHEMBL5963825

SCHEMBL5963825

Cc1ccc(C)c(-c2ccc(CN(C)CC(O)c3ccccc3)cc2)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.61
KMT2A Q03164 6/20 0.54
MEN1 O00255 5/20 0.54
KDM4E B2RXH2 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
TAAR1 Q96RJ0 1/20 0.51
HTT P42858 1/20 0.43
AOC3 Q16853 2/20 0.41
ALDH1A1 P00352 3/20 0.40
FAAH O00519 1/20 0.37
RAB9A P51151 1/20 0.37
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
ATM Q13315 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
DNM1 Q05193 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5964317 0.88 CNR2 (0.58) CNR2KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL5963980 0.88 CNR2 (0.47) CNR2KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL5963927 0.87 CNR2 (0.70) CNR2KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL5964021 0.87 CNR2 (0.57) CNR2KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL5964627 0.87 MEN1 (0.50) CNR2KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL5964071 0.86 CNR2 (0.56) CNR2KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL5964068 0.85 CNR2 (0.67) CNR2KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL5964624 0.84 CNR2 (0.46) CNR2KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL5964036 0.81 CNR2 (0.61) CNR2KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL4348629 0.80 HTT (0.52) CNR2KMT2AMEN1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060052315-A1 Cb 1/cb 2 receptor ligands and their use in the treatment of pain ASTRAZENECA AB (SE) 2006-03-09 US claimed
EP-1594856-A1 CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN AstraZeneca AB (SE) 2005-11-16 EP claimed
WO-2004060882-A1 CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2004-07-22 WO claimed
US-20060052315-A1 Cb 1/cb 2 receptor ligands and their use in the treatment of pain ASTRAZENECA AB (SE) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052315-A1 Cb 1/cb 2 receptor ligands and their use in the treatment of pain CNR1, CNR2, OPRL1 CNR2 2/4885KMT2A 2160/4885MEN1 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.